New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 25, 2013
10:07 EDTSKS, CHMT, WPRT, EBAY, SRPT, OMCL, STRZA, RHT, PKOH, MMC, FOR, BRO, BXP, BIOS, BMR, AON, AMZN, ACT, ACNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Accenture (ACN) initiated with an Overweight at Evercore... Actavis (ACT) initiated with an Overweight at Morgan Stanley... Amazon.com (AMZN) initiated with a Buy at ISI Group... Aon Corp. (AON) initiated with a Market Perform at Wells Fargo... BioMed Realty (BMR) initiated with a Neutral at Goldman... BioScrip (BIOS) initiated with a Buy at SunTrust... Boston Properties (BXP) initiated with an Overweight at Evercore... Brown & Brown (BRO) initiated with a Market Perform at Wells Fargo... Forestar Group (FOR) initiated with a Buy at DA Davidson... Marsh & McLennan (MMC) initiated with an Outperform at Wells Fargo... Park-Ohio (PKOH) initiated with an Outperform at Imperial Capital... Red Hat (RHT) initiated with an Outperform at Northland Securities... Starz (STRZA) initiated with a Sell at Stifel Nicolaus... Starz (STRZA) initiated with an Underweight at Evercore... Omnicell (OMCL) initiated with a Buy at Benchmark Co... Sarepta (SRPT) initiated with an Outperform at Cowen... eBay (EBAY) initiated with a Positive at Susquehanna... Westport Innovations (WPRT) initiated with a Market Perform at Raymond James... Chemtura (CHMT) initiated with a Buy at Sidoti... Saks (SKS) initiated with a Buy at Maxim.
News For ACN;ACT;AMZN;AON;BMR;BIOS;BXP;BRO;FOR;MMC;PKOH;RHT;STRZA;OMCL;SRPT;EBAY;WPRT;CHMT;SKS From The Last 14 Days
Check below for free stories on ACN;ACT;AMZN;AON;BMR;BIOS;BXP;BRO;FOR;MMC;PKOH;RHT;STRZA;OMCL;SRPT;EBAY;WPRT;CHMT;SKS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
September 10, 2014
10:37 EDTAMZN, EBAYChannelAdvisor data shows soft August for eBay, says RW Baird
RW Baird analyst Colin Sebastian says ChannelAdvisor same-store-sales data for August confirms eBay (EBAY) had a soft month. Sebastian believes eBay's new Defect Rate may be pressuring sellers. He remains "somewhat cautious" on eBay in the near-term, but keeps an Outperform rating on the name. Sebastian noted that same-store-sakes data for Amazon.com (AMZN) is more positive.
10:31 EDTAMZNChannelAdvisor says August Amazon SSS up 45.1%, eBay up 5.9%
Subscribe for More Information
10:26 EDTAMZNDiscovery CEO says likes doing deals with Netflix, Amazon
CEO David Zaslav says Comcast (CMCSA)/Time Warner Cable (TWC) deal "presents some serious issues," is talking to FCC about deal. Says will be opportunistic with international acquisitions, but "We don't feel like we need to acquire anything at this point." Says has more subscribers than ESPN with Europsport. Comments made at the Goldman Sachs Communacopia Conference.
10:18 EDTEBAYeBay falls, levels to watch
Subscribe for More Information
10:00 EDTEBAYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:38 EDTEBAY, AMZNActive equity options trading on open
Subscribe for More Information
09:22 EDTEBAYOn The Fly: Pre-market Movers
HIGHER: Twitter (TWTR), up 2.8% after upgraded at UBS... SunEdison (SUNE), up 2.7% after Google (GOOG) to provide $145M investment in the company's Regulus solar plant... Camtek (CAMT), up 15% after receiving new orders of $3.0M from large OSAT... Doral Financial (DRL), up 12.5% after announcing sale of approximately $430M in assets... Imperva (IMPV), up 1.5% after upgraded at Oppenheimer... Mandalay Digital (MNDL), up 13.7% after updating its guidance. UP AFTER EARNINGS: Land's End (LE), up 8.7%... Palo Alto (PANW), up 4.4%. LOWER: eBay (eBAY), down 2.6% after downgraded at Piper Jaffray following yesterday's launch of Apple Pay (AAPL)... Mobileye (MBLY), down 2.5% after downgraded at Deutsche Bank... Krispy Kreme (KKD), down 2% after Q2 earnings report... GT Advanced (GTAT), down 7% after downgraded at Goldman and Piper Jaffray... Boyd Gaming (BYD), down 3.3% after downgraded at Morgan Stanley... Urban Outfitters (URBN), down 2% after reporting Q3 SSS were so far in the low single-digits negative... Armada Hoffler (AHH), down 6% after filing to sell 5M shares of common stock... AvalonBay (AVB), down 1.8% after to sell 4.5M shares in a forward sales agreement with Goldman... AngloGold (AU), down 12% after announcing plans to restructure its international mining under a new company and saying equity capital raising being contemplated.
09:02 EDTACTActavis won't see serious long-term impact from rejection, says Sterne Agee
After the FDA's Cardiovascular and Renal Drugs Advisory Committee voted to recommend against approval of Actavis' New Drug Application for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension, Sterne Agee does not thinks the vote is very meaningful to the company's longer-term growth and earnings potential. The firm says that removing the product from its revenue outlook causes its 2018 EPS estimate for the company to drop by less than 1%. The firm still thinks the company can easily reach its 2017 EPS target of about $20. Sterne Agee keeps a $272 price target and Buy rating on the shares.
08:56 EDTACTFDA advisors recommend against approval of Actavis' nebivolol/valsartan combo
Actavis last night confirmed that the FDA's Cardiovascular and Renal Drugs Advisory Committee has voted to recommend against approval of Actavis' New Drug Application for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension. The committee vote was six to four recommending against approval. The committee recommendation is not binding on the FDA, which makes the final decision regarding approval. Actavis expects FDA action on its NDA for the fixed-dose combination of nebivolol and valsartan by the fourth quarter of 2014. Actavis' Senior VP, Global Brands Research and Development, David Nicholson, said, "Although we are disappointed in the Committee's recommendation regarding the fixed-dose combination of nebivolol and valsartan, we remain fully committed to supporting the NDA for this important potential new treatment option for patients with hypertension. We remain confident in the safety and efficacy of the combination of these two widely used and well-tolerated treatments, and we look forward to working with the FDA as it completes its review." Shares of Actavis are down more than 2% in pre-market trading following yesterday's committee recommendation.
08:20 EDTEBAYeBay to see more competition than expected from Apple, says Pacific Crest
Pacific Crest believes that Apple Pay could hurt sentiment towards eBay's (EBAY) longer term opportunity, while Apple (AAPL) is more focused on e-commerce than the firm had anticipated, creating greater competition for PayPal. The firm keeps a Sector Perform rating on eBay.
08:02 EDTAMZNTrex launches Outdoor Lighting on Amazon.com
Trex (TREX) has officially entered the e-commerce marketplace with the launch of its high-performance Trex Outdoor Lighting collection on Amazon.com (AMZN). The first product line to be sold by Trex online, Trex Outdoor Lighting will join other Trex-branded products currently available on Amazon through Trex licensees, including Trex Outdoor Furniture, Trex RainEscape and Trex Pergola.
07:56 EDTRHTRed Hat October volatility elevated into Q2 and outlook
Subscribe for More Information
07:24 EDTRHTRed Hat coverage assumed with a Neutral at MKM Partners
Subscribe for More Information
07:22 EDTEBAYeBay weakness on Apple news a buying opporutnity, says Bernstein
Subscribe for More Information
06:38 EDTEBAYeBay downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Gene Munster downgraded eBay (EBAY) shares to Neutral from Overweight saying Apple's (AAPL) new payment system is likely to disrupt the mobile payments market. Munster believes the "unknown competitive threat" of Apple Pay will further weigh on eBay's multiple over the next six months. He lowered his price target for the stock to $55 from $63.
06:24 EDTAMZNAmazon to debut Fire Phone in U.K.
Subscribe for More Information
September 9, 2014
17:06 EDTACTFDA panel votes against Actavis blood pressure pill, Bloomberg says
FDA advisers said that Actavis's experimental pill that combines two existing drugs to lower high blood pressure doesn’t provide a clinically meaningful benefit over the two drugs alone, says Bloomberg. The advisory panel voted 6 to 4 against recommending the treatment, added Bloomberg. Shares of Actavis are trading down almost 1% in after-hours trading. Reference Link
16:00 EDTAMZNiPath S&P 500 VIX Short-Term Futures up 74c to 28.25
Subscribe for More Information
15:37 EDTCHMTGabelli raises stake in Chemtura to 8.58% from 7.58%
Subscribe for More Information
15:05 EDTAMZNAmazon.com falls to session lows, levels to watch
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use